Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Poor CD4+ T Cell Immunogenicity Limits Humoral Immunity to P. falciparum Transmission-Blocking Candidate Pfs25 in Humans

Frontiers in Immunology(2021)10.3389/fimmu.2021.732667Source: DataRank Database

Poor CD4+ T Cell Immunogenicity Limits Humoral Immunity to P. falciparum Transmission-Blocking Candidate Pfs25 in Humans is a research paper published in Frontiers in Immunology (2021). On theSindex it has a DataRank of 0. It has been cited 9 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access9 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 1.70)OA: goldTopics (98)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (17)

Arianna Marini ORCID,Carolyn M. Nielsen ORCID,Gaurav Gupta ORCID,David Mekhaiel ORCID,Thao Pham ORCID

Live enrichment

PubMed:34659219 PMC:PMC8515144 OpenAlex:https://openalex.org/W3204829583

Wellcome Trust

Grant: 209200/Z/17/Z

European Commission

Grant: 305282

A Multi-Stage Malaria Vaccine

Wellcome Trust

Grant: 209200

The impact of vaccine platform on the cellular drivers of humoral immunity

FWCI

1.70

Citation Percentile

0.8%

Citation Trend

2022

2023

2024

goldLicense: cc-by

journalhttps://www.frontiersin.org/articles/10.3389/fimmu.2021.732667/pdf

publisherhttps://www.frontiersin.org/articles/10.3389/fimmu.2021.732667/pdf

publisherhttps://www.frontiersin.org/articles/10.3389/fimmu.2021.732667/full

journalhttps://doi.org/10.3389/fimmu.2021.732667

repositoryhttps://pubmed.ncbi.nlm.nih.gov/34659219

Fields of Study

Malaria Research and ControlHIV Research and Treatmentvaccines and immunoinformatics approaches0301 basic medicine03 medical and health sciencesAdolescentAdultAnimalsAntibodies, ProtozoanB-LymphocytesCD4-Positive T-LymphocytesCells, CulturedDisease Models, AnimalEpitopesFemaleHumansImmunity, HumoralImmunogenicity, VaccineMalaria VaccinesMalaria, FalciparumMaleMiceMice, Inbred BALB CMiddle AgedPlasmodium falciparumProtozoan ProteinsRecombinant ProteinsSpecies SpecificityVaccinationYoung Adult

MeSH Terms

Immunogenicity, VaccineAdolescentAdultAnimalsAntibodies, ProtozoanEpitopesB-LymphocytesCells, CulturedDisease Models, AnimalFemaleHumansMaleMice, Inbred BALB CMiddle AgedPlasmodium falciparumRecombinant ProteinsSpecies SpecificityVaccinationCD4-Positive T-LymphocytesProtozoan ProteinsMalaria, FalciparumMalaria VaccinesMiceYoung AdultImmunity, Humoral

Keywords

ImmunogenicityVirologyAntigenImmunologyEpitopeVacciniaBiologyVaccinationAntibodyMedicineRecombinant DNAVaccineCd4+P. FalciparumTransmission BlockingPfs25AdultCD4-Positive T-LymphocytesMaleAdolescentPlasmodium falciparumProtozoan Proteins610Antibodies, ProtozoanEpitopesMiceYoung AdultImmunogenicity, VaccineSpecies SpecificityMalaria VaccinesAnimalsHumansMalaria, FalciparumCells, CulturedB-LymphocytesMice, Inbred BALB CRC581-607Middle AgedRecombinant ProteinsImmunity, HumoralDisease Models, AnimalFemaleImmunologic diseases. Allergy

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Poor CD4+ T Cell Immunogenicity Limits Humoral Immunity to P. falciparum Transmission-Blocking Candidate Pfs25 in Humans

FAIR Checklist

Authors (17)

Funding (3 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)